Hospital
Steward Norwood Hospital, INC.
Steward Norwood Hospital, INC. was paid $8.47M by Medicaid between Jan 2018 and Sep 2024, across 182 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoSTEWARD NORWOOD HOSPITAL, INC.
NORWOOD, MA 02062
NORWOOD, MA 02062
33aNPI1952613416assigned 07/12/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.47M
24GClaims198,560
24DCodes billed182
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#44 of 66
Median peer was paid$29.11M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RENNA, JAMES controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 86,068 | $3.70M | |
| 2019 | 76,181 | $3.17M | |
| 2020 | 26,454 | $1.09M | |
| 2021 | 3,478 | $149K | |
| 2022 | 3,045 | $160K | |
| 2023 | 1,800 | $113K | |
| 2024incomplete | 1,534 | $88K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 10,397 | 9,473 | $1.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 7,594 | 6,919 | $1.07M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 6,409 | 5,696 | $947K |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 3,565 | 2,851 | $877K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 2,327 | 2,177 | $358K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 1,496 | 1,380 | $345K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 1,820 | 1,672 | $287K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.0% | 4,594 | 4,539 | $255K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.8% | 474 | 461 | $241K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 1,370 | 1,004 | $165K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 2,590 | 818 | $151K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 3,919 | 3,412 | $134K |
170 more codes
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.4% | 1,705 | $120K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 940 | $104K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 5,594 | $100K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 806 | $99K |
| 59025 | Fetal non-stress test | 1.1% | 465 | $95K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 293 | $85K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 573 | $78K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 258 | $74K |
| G0378 | Hospital observation service, per hour | <1% | 3,089 | $70K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 72 | $63K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,780 | $62K |
| 87631 | <1% | 645 | $57K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,141 | $52K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 103 | $47K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,157 | $44K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 295 | $41K |
| 76642 | <1% | 441 | $40K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 210 | $37K |
| ATP14 | <1% | 4,225 | $35K | |
| 93971 | <1% | 102 | $33K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,726 | $33K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 125 | $30K |
| 84600 | <1% | 2,630 | $28K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,452 | $28K |
| 80053 | Comprehensive metabolic panel | <1% | 10,078 | $28K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,769 | $23K |
| 84484 | <1% | 4,385 | $22K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 856 | $21K |
| 71250 | <1% | 237 | $19K | |
| 76536 | <1% | 181 | $18K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 338 | $18K |
| 77080 | <1% | 316 | $18K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 69 | $16K |
| 73630 | <1% | 528 | $15K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 69 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 414 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,943 | $15K |
| 99219 | <1% | 34 | $14K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,168 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,302 | $13K |
| 72100 | <1% | 352 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,218 | $13K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,630 | $12K |
| 81025 | <1% | 2,427 | $12K | |
| 88142 | <1% | 701 | $12K | |
| 83690 | <1% | 2,111 | $10K | |
| 77065 | Tomosynthesis, mammo | <1% | 122 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,839 | $9K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 140 | $9K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 63 | $8K |
| ATP08 | <1% | 1,311 | $8K | |
| 71271 | <1% | 177 | $8K | |
| 83605 | <1% | 1,385 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 63 | $8K |
| 73610 | <1% | 341 | $8K | |
| 81001 | <1% | 3,637 | $7K | |
| 84702 | <1% | 576 | $7K | |
| 76770 | <1% | 41 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,104 | $6K |
| 85379 | <1% | 906 | $6K | |
| 87081 | <1% | 1,135 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 44 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 159 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 46 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 44 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 374 | $5K |
| 83735 | <1% | 1,362 | $5K | |
| 73030 | <1% | 297 | $5K | |
| 86850 | <1% | 668 | $5K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 745 | $4K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 29 | $4K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 33 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 28 | $4K |
| 74018 | <1% | 183 | $4K | |
| 87040 | <1% | 745 | $4K | |
| 73130 | <1% | 179 | $4K | |
| 88313 | <1% | 402 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 143 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 143 | $3K |
| 83880 | <1% | 253 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 149 | $3K |
| 90715 | <1% | 115 | $3K | |
| ATP15 | <1% | 380 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 654 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,534 | $3K |
| 81003 | <1% | 2,012 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,947 | $2K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 820 | $2K |
| 97161 | <1% | 44 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,648 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $2K |
| 85027 | <1% | 581 | $2K | |
| 87186 | <1% | 432 | $2K | |
| 12001 | <1% | 12 | $2K | |
| 86900 | <1% | 714 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 989 | $2K |
| 84703 | <1% | 285 | $2K | |
| 73110 | <1% | 73 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 169 | $2K |
| 86901 | <1% | 715 | $1K | |
| 93017 | <1% | 14 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 26 | $1K |
| 85610 | <1% | 922 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 842 | $1K |
| 88342 | <1% | 439 | $1K | |
| 80050 | General health panel | <1% | 94 | $1K |
| 87077 | <1% | 397 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 224 | $1K |
| 82947 | <1% | 1,751 | $1K | |
| 76801 | <1% | 14 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,975 | $1K |
| 87070 | <1% | 234 | $1K | |
| 73502 | <1% | 56 | $982.80 | |
| 73564 | <1% | 30 | $933.22 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 915 | $895.28 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 791 | $812.56 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 178 | $698.33 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 27 | $633.42 |
| 86140 | <1% | 174 | $570.43 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $567.52 |
| 87147 | <1% | 132 | $537.86 | |
| 80177 | <1% | 54 | $530.77 | |
| 87205 | <1% | 187 | $475.86 | |
| 85244 | <1% | 61 | $475.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $463.76 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,942 | $454.41 |
| 85280 | <1% | 61 | $450.22 | |
| J3490 | Unclassified drugs | <1% | 123 | $411.64 |
| 88304 | <1% | 160 | $392.82 | |
| 96376 | <1% | 142 | $389.61 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 753 | $333.07 |
| 80076 | <1% | 603 | $322.50 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 198 | $294.46 |
| 85652 | <1% | 178 | $277.86 | |
| 73140 | <1% | 16 | $250.48 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 533 | $227.01 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 932 | $223.93 |
| 85651 | <1% | 105 | $217.42 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 226 | $209.62 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 155 | $194.52 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 866 | $189.95 |
| 85007 | <1% | 130 | $184.08 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,324 | $182.57 |
| 73562 | <1% | 38 | $150.79 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 95 | $124.32 |
| 85730 | <1% | 28 | $86.80 | |
| 81015 | <1% | 31 | $43.96 | |
| ATP03 | <1% | 16 | $34.25 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 368 | $31.99 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 152 | $31.75 |
| 82553 | <1% | 17 | $17.58 | |
| 82565 | <1% | 46 | $14.65 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 49 | $9.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,196 | $6.86 |
| 82550 | <1% | 17 | $4.70 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $2.36 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 65 | $0.60 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 46 | $0.22 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 40 | $0.00 |
| 80061 | Lipid panel | 0% | 147 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 15 | $0.00 |
| 84520 | 0% | 29 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 295 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 161 | $0.00 |
| 80329 | 0% | 13 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 91 | $0.00 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRENNA, JAMES (CHIEF FINANCIAL OFFICER)
Parent organizationSTEWARD HEALTH CARE SYSTEM LLC
| Provider | Location | Paid |
|---|---|---|
| Steward Holy Family Hospital, INC. | Methuen, MA | $70.80M |
| Steward Good Samaritan Medical Center, INC. | Brockton, MA | $64.10M |
| Steward Carney Hospital, INC. | Dorchester Center, MA | $56.76M |
| Steward ST. Elizabeth's Medical Center of Boston, INC. | Boston, MA | $32.53M |
| Steward ST. Elizabeth's Medical Center of Boston, INC. | Boston, MA | $1.90M |
| Steward Holy Family Hospital, INC. | Methuen, MA | $1.06M |
| New England Sinai Hospital, a Steward Family Hospital, INC. | Stoughton, MA | $136K |
| Steward Carney Hospital, INC. | Dorchester Center, MA | $52K |
| Steward Good Samaritan Medical Center, INC. | Brockton, MA | $29K |
| Morton Hospital, a Steward Family Hospital, INC. | Taunton, MA | $11K |
| Steward ST. Anne's Hospital Corporation | Fall River, MA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.